



HAL
open science

Feasibility and safety of ultra-low volume ventilation (≤ 3 ml/kg) combined with extra corporeal carbon dioxide removal (ECCO2R) in acute respiratory failure patients

Clément Monet, Thomas Renault, Yassir Aarab, Joris Pensier, Albert Prades, Ines Lakbar, Clément Le Bihan, Mathieu Capdevila, Audrey de Jong, Nicolas Molinari, et al.

► To cite this version:

Clément Monet, Thomas Renault, Yassir Aarab, Joris Pensier, Albert Prades, et al.. Feasibility and safety of ultra-low volume ventilation (≤ 3 ml/kg) combined with extra corporeal carbon dioxide removal (ECCO2R) in acute respiratory failure patients. *Critical Care*, 2024, 28 (1), pp.433. 10.1186/s13054-024-05168-8 . hal-04858019

HAL Id: hal-04858019

<https://hal.science/hal-04858019v1>

Submitted on 30 Dec 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Feasibility and safety of ultra-low volume ventilation (≤ 3 ml/kg) combined with extra corporeal carbon dioxide removal (ECCO₂R) in acute respiratory failure patients

Clément Monet^{1 2}, Thomas Renault¹, Yassir Aarab^{1 2}, Joris Pensier^{1 2}, Albert Prades¹, Ines Lakbar^{1 2}, Clément Le Bihan¹, Mathieu Capdevila^{1 2}, Audrey De Jong^{3 4}, Nicolas Molinari^{5 6}, Samir Jaber^{7 8}

¹ Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, PhyMedExp, INSERM U1046, CNRS UMR, University of Montpellier, 9214, Montpellier Cedex 5, France.

² PhyMedExp, INSERM U1046, CNRS UMR, University of Montpellier, 9214, Montpellier, France.

³ Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, PhyMedExp, INSERM U1046, CNRS UMR, University of Montpellier, 9214, Montpellier Cedex 5, France. a-de_jong@chu-montpellier.fr.

⁴ PhyMedExp, INSERM U1046, CNRS UMR, University of Montpellier, 9214, Montpellier, France. a-de_jong@chu-montpellier.fr.

⁵ Medical Information, IMAG, CNRS, Centre Hospitalier Regional Universitaire de Montpellier, Univ Montpellier, Montpellier, France.

⁶ Département d'informatique Médicale, CHRU Montpellier, Institut Desbrest de Santé Publique (IDESP) INSERM, Université de Montpellier, Montpellier, France.

⁷ Department of Anesthesia and Intensive Care Unit, Regional University Hospital of Montpellier, St-Eloi Hospital, PhyMedExp, INSERM U1046, CNRS UMR, University of Montpellier, 9214, Montpellier Cedex 5, France. s-jaber@chu-montpellier.fr.

⁸ PhyMedExp, INSERM U1046, CNRS UMR, University of Montpellier, 9214, Montpellier, France. s-jaber@chu-montpellier.fr.

Keywords:

Acute respiratory distress syndrome; ECCO₂R; Extracorporeal carbon dioxide removal; Intensive care; Ventilator-induced lung injury.

*Correspondence:

Audrey De Jong ; a-de_jong@chu-montpellier.fr; Samir Jaber s-jaber@chu-montpellier.fr

Abbreviations

V_t Tidal volume

ECCO₂R Extra corporeal carbon dioxide removal

ICU Intensive Care Unit

IQR Inter quartile range

PaCO₂ Carbon dioxide partial pressure

PaO₂ /FiO₂ Arterial to inspired O₂ fraction ratio

Abstract

Background:

Ultra-protective ventilation is the combination of low airway pressures and tidal volume (V_t) combined with extra corporeal carbon dioxide removal (ECCO₂R). A recent large study showed no benefit of ultra-protective ventilation compared to standard ventilation in ARDS (Acute Respiratory Distress Syndrome) patients. However, the reduction in V_t failed to achieve the objective of less than or equal to 3 ml/kg predicted body weight (PBW). The main objective of our study was to assess the feasibility of the ultra-low volume ventilation ($V_t \leq 3$ ml/kg PBW) facilitated by ECCO₂R in acute respiratory failure patients.

Methods:

Retrospective analysis of a prospective cohort of patients with either high or low blood flow veno-venous ECCO₂R devices. A session was defined as a treatment of ECCO₂R from the start to the removal of the device (one patient could have one more than one session). Primary endpoint was the proportion of sessions during which a V_t less or equal to 3 ml/kg PBW at 24 h after the start of ECCO₂R was successfully achieved for at least 12 h. Secondary endpoints were respiratory variables, rate of adverse events and outcomes.

Results:

Forty-five ECCO₂R sessions were recorded among 41 patients. Ultra-low volume ventilation (tidal volume ≤ 3 ml/kg PBW, success group) was successfully achieved at 24 h in 40.0% sessions (18 out of 45 sessions, confidence interval 25.3-54.6%). At 24 h, tidal volume in the failure group was 4.1 [3.8-4.5] ml/kg PBW compared to 2.1 [1.9-2.5] in the success group ($p < 0.001$). After multivariate analysis, blood flow rate was significantly associated with success of ultra-low volume ventilation (adjusted OR per 100 ml/min increase 1.51 (95%CI 1.21-1.90, $p = 0.0003$).

Conclusion:

Ultra-low volume ventilation (≤ 3 ml/kg PBW) was feasible in 18 out of 45 sessions. Higher blood flow rates were associated with the success of ultra-low volume ventilation.

Take-home message

In a cohort of 41 patients treated with ECCO2R, ultra-low volume ventilation (tidal volume \leq 3 ml/kg of predicted body weight) was feasible for at least 12 h with a success rate of 40.0% (confidence interval 25.3–54.6%). Higher blood flow rates were associated with the success of ultra-low volume ventilation.

140-character tweet

Ultra-low volume ventilation (tidal volume \leq 3 ml/kg) is feasible with ECCO2R when using higher blood flow rates.

Background

Acute respiratory failure is the leading cause of Intensive Care Unit (ICU) admission and remains associated with high mortality, especially in patients requiring invasive mechanical ventilation [1, 2]. Although necessary, invasive ventilation can contribute to pulmonary injury and inflammation, commonly referred to as «ventilator-induced lung injury» (VILI) [3]. Different mechanisms can be implicated: barotrauma, volutrauma, atelectrauma and biotrauma [4, 5]. Protective ventilation strategies (low tidal volume (V_t) of 4–8 ml/kg of predicted body weight (PBW) and plateau pressure (Pplat) lower than 30 cmH₂O [6]) have proven to limit VILI and improve outcomes in ARDS (Acute Respiratory Distress Syndrome) patients and in ventilated patients without underlying lung injury [6, 7]. However, in some ARDS patients treated with protective ventilation strategy, hyperinflation and lung injury could still occur when lung protective ventilation targets are not met [8, 9]. These patients could justify and benefit from a better control of V_t and Pplat [10, 11]. The limiting factor of this strategy is the carbon dioxide accumulation and respiratory acidosis. Extra corporeal carbon dioxide removal (ECCO2R) addresses this issue by removing carbon dioxide via an extracorporeal circuit and maintaining pH and PaCO₂ within physiological range values [12]. This combination has been described as “ultra-protective ventilation” [12, 13]. However, the lack of high-quality data and the high heterogeneity in devices and practices made it difficult to conclude on efficacy regarding patient-centered outcomes and ECCO 2R might even be detrimental [14, 15]. Recently, a large randomized controlled trial showed no benefit of ultra-protective ventilation compared to standard ventilation in ARDS patients [16]. However, in this study the reduction in V_t failed to achieve the objective of “less than or equal to 3 ml/kg PBW” and ultraprotective ventilation was only maintained for a short period of time. We made the hypothesis that difficulties to achieve ultra-low volume ventilation ($V_t \leq$ 3 ml/kg PBW) could be explained by insufficient CO₂ removal. The main objective of this study was to assess the feasibility of ultra-low volume ventilation ($V_t \leq$ 3 ml/kg PBW) in acute respiratory failure patients. Secondary objectives were to evaluate

efficacy and safety of ultra-low volume ventilation as well as to identify factors associated with the feasibility of ultra-low volume ventilation.

Methods

Patients and ethics

We conducted a retrospective, pragmatic, descriptive analysis of a cohort of patients who consecutively underwent ECCO 2 R treatment in a single French center. All patients admitted from June 2014 to December 2022, who presented an acute respiratory failure and were treated with ECCO 2 R therapy at any point during their ICU stay were included. The Institutional Review Board of Montpellier University Hospital approved the study (2019_IRB-MTP_05-25).

Collected data

Demographic characteristics (age, gender, body mass index), comorbidities and severity scores (Simplified Acute Physiology Score II, SAPS II, and the Sequential Organ Failure Assessment, SOFA[17, 18]) were collected at admission. Respiratory variables (tidal volume, plateau pressure, positive end-expiratory pressure, driving pressure, minute ventilation) and gas exchanges (PaO₂/ FIO₂ ratio, PaCO₂, pH) were prospectively collected at the start of ECCO₂R (H0) and 4, 24 and 48 h after initiation of ECCO₂R (referred in this study as H0, H4, H24, H48). Mechanical power was calculated using the simplified formula described by Gattinoni et al. [19]. ECCO₂R technical characteristics were also recorded: cannula type and size, blood flow rates, and anticoagulation methods. Ventilatory ratio (VR), which is a composite variable reflective of dead space and shunt, was computed as previously described [20] (see Supplementary appendix). ECCO₂R-related adverse events (ECCO₂R-AE) were recorded and classified as mechanical and clinical [21] (complete definitions are provided in the Supplementary appendix). Indication and duration of ECCO₂R, adjunctive ARDS treatments, time from intubation to ECCO₂R, duration of invasive mechanical ventilation, duration of ICU stay, and 90-day survival were also recorded.

ECCO2R treatment

Extra corporeal carbon dioxide removal treatment was performed with 4 different veno-venous devices: Hemolung Respiratory Assist System® (ALung Technologies, Pittsburgh, USA); iLA activve® (Xenios, Fresenius medical care company, Germany), Primalung® and Primalung + ® (Baxter Healthcare, Sweden). A percutaneous venous access was obtained. The femoral or jugular vein was catheterized at physicians' discretion. Devices were classified as: low blood flow ECCO 2R devices (blood flow less than 500 ml/min) and high blood flow ECCO2R devices (blood flow greater than or equal to 1000 ml/min). Low blood flow ECCO2R devices were: (1) Primalung® which is a gas exchanger for CO₂ removal on the Prismaflex system with a 0.32m² heparin coated polymethylpentene (PMP) membrane (2) Primalung + ® with a 0.8m² phosphorylcholine coated PMP membrane (3) Hemolung Respiratory Assist System® with a 0.59m² siloxane and heparin coated hollow fibers membrane. The high blood flow ECCO 2R device was the iLA activve® with a heparin coated 1.3m² PMP hollow fiber membrane. Anticoagulation was left to the clinician discretion based on coagulation test, manufacturer instructions and clinical data.

Protocol of the study

The ECCO2R initiation protocol was as follows: the targeted blood flow was the maximum blood flow according to available data and/or manufacturer (for the high blood flow ECCO2R devices, we arbitrarily limited the blood flow to 2000 ml/min). When the targeted blood flow (or maximum achievable blood flow) was reached, sweep gas flow was increased from 0 L/min to 10 L/min with 2 L/min steps every 30 min. Simultaneously V_t was decreased every 30 min by 0.5 ml/kg with an objective of V_t ≤ 3 ml/kg PBW. V_t reduction was stopped when the patient developed signs of poor tolerance defined as follows: (1) PaCO₂ increasing more than 20% from the start of ECCO2R with a value of pH < 7.3, as previously described [21]; (2) discontinuation of ECCO2R therapy due to mechanical complication (membrane clotting, pump malfunction, etc.); (3) discontinuation of ECCO2R therapy due to clinical complication (hypoxemia, hemolysis, bleeding, etc.).

Endpoints

The primary endpoint was the proportion of sessions during which a $V_t \leq 3$ ml/kg PBW was successfully achieved at 24 h after the start of ECCO2R. We defined “ECCO2R session” as a treatment with ECCO 2R from the start to the removal of the device, one patient could have one or more if treated again with ECCO2R for a new indication (same or different ICU stay). If a circuit change was necessary during a session, we still considered it as a single session. We then defined two groups: (1) the “success group” and (2) the “failure group” based on whether the endpoint was reached. Secondary end- points included: duration of ECCO2 R, respiratory variables, ventilatory settings at H0, H4, H24 and H48, ECCO2R-related adverse events and 90-day survival.

Statistical analysis

First, a descriptive analysis was performed overall, in the success group and in the failure group. For continuous data, the Gaussian distribution was checked using Shapiro–Wilk or Kolmogorov–Smirnov tests. Quantitative variables were expressed as mean (\pm standard deviation (SD)) or as median with interquartile ranges [IQR] (Gaussian or non-Gaussian variables) and compared using the Student t test or Mann–Whitney test respectively. Paired quantitative variables were compared using a paired Student t-test or Wilcoxon signed-rank test when appropriate (Gaussian or non-Gaussian variables). Qualitative variables were expressed as numbers (%) and compared using the chi-square test or Fisher’s exact test, as appropriate (when expected frequencies were less than five). Paired qualitative variables were compared with a McNemar test. Then, a multivariate logistic regression model was performed to provide adjusted results of success of ultra-low volume ventilation (primary out- come), considering a priori the variables age, body mass index, SAPS II, driving pressure and blood flow rate (per 100 ml/min increase). These factors were entered into the multivariate model, and a final model including only significant variables was computed. Adjusted odds ratio (OR) with 95% confidence intervals (CI) were computed. Statistical significance was considered at $p < 0.05$; p values were two-tailed. All analyses were done with the use of SAS Enterprise Guide (version 7.13) or statistical soft- ware R (version 4.0.3; R Foundation for Statistical Computing). Regarding 90-day survival, patients who had more than one session were analyzed in the group cor- responding to the first session.

Results

Sessions characteristics

We report 45 sessions of ECCO 2R in our unit from June 2014 to December 2022 among 41 patients. Among the 45 sessions: 18 sessions were included in the success group (≤ 3 ml/kg PBW) and 27 sessions in the failure group (> 3 ml/kg PBW). One patient was included in both groups (1 session in each group). Sessions characteristics can be found in Table 1. Demographics did not significantly differ between the two groups. SOFA and SAPS II score were high without significant difference between groups (10 [6–13] vs. 10 [7–15] $p = 0.49$ and 54 [40–58] vs. 47 [34–65] $p = 0.83$, respectively) (Table 1). Indication for ECCO2 R in the overall population was ARDS for 37 (82%) sessions without a significant difference between groups. Respiratory variables and ventilatory settings before the start of ECCO2R were not significantly different between the two groups, except for driving pressure (14.0 [10.3–18.8] cmH₂O in the failure group versus Page 4 of 12 Monet et al. Critical Care (2024) 28:433 20.0 [16.3–22.8] cmH₂O in the success group, $p = 0.018$) (Table 2). Adjunctive ARDS treatments prior to ECCO2 R were more frequently applied in the success group (61.1% vs 29.6%, $p = 0.036$).

Technical characteristics of extracorporeal CO₂ removal

ECCO2R was maintained for 3 [1–4] days. The PrismaLung® device was used for 15 (33.3%) sessions, the PrismaLung + ® for 8 (17.8%) sessions, the Hemolung® device was used for 2 (4.4%) sessions and the iLA activve® device was used for 20 (44.4%) sessions. Twenty-nine ECCO2R sessions (64.4%) were performed using anticoagulation with unfractionated heparin. Sixteen (35.6%) sessions were performed without anticoagulation. Cannula sizes and insertion sites can be found in Table 3.

Table 1 Overall sessions characteristics at baseline and comparison between the failure group and the success group

Sessions characteristics	Overall sessions (n = 45)	Failure group (n = 27)	Success group (n = 18)	p value
Age, years	60 [48–65]	60 [52–63]	57 [41–66]	0.93
Female gender	13 (29)	9 (33)	4 (22)	0.42
Size, cm	172 [165–176]	170 [165–175]	174 [170–176]	0.13
Weight, kg	80 [69–84]	80 [70–85]	75 [63–84]	0.32
Body mass index, kg/m ²	27 [23–28]	27 [24–29.5]	25 [20–28]	0.21
Reason for ICU admission				
Medical	26 (58)	13 (48)	13 (72)	0.11
Surgical	19 (42)	14 (52)	5 (28)	0.11
SAPS II	52 [36–62]	54 [40–58]	47 [34–65]	0.83
SOFA score	10 [7–13]	10 [6–13]	10 [7–15]	0.49
Indication for ECCO ₂ R				
ARDS (Pulmonary/non-pulmonary)	37 (82)	22 (82)	15 (83)	0.99
Pulmonary	31 (69)	16 (59)	15 (83)	0.11
Pneumonia	9 (20)	5 (19)	4 (22)	0.99
Aspiration	7 (16)	2 (7)	5 (28)	0.1
Influenzae	2 (4)	1 (4)	1 (6)	0.99
Pulmonary complications of surgery	7 (16)	5 (19)	2 (11)	0.68
SARS-CoV-2 pneumonia	5 (11)	3 (11)	2 (11)	0.99
Antisynthetase syndrome	1 (2)	0 (0)	1 (6)	0.4
Non-pulmonary	6 (13)	6 (22)	0	0.07
SIRS/Sepsis	2 (4)	2 (7)	0	0.51
Transfusion Related Acute Lung Injury	4 (9)	4 (15)	0	0.14
Non-ARDS	8 (18)	5 (19)	3 (17)	0.99
Ultra-protective ventilation	3 (7)	2 (7)	1 (6)	0.99
Pulmonary fibrosis	2 (4)	0 (0)	2 (11)	0.15
Hypercapnic respiratory failure	1 (2)	1 (4)	0 (0)	0.99
Weaning failure	2 (4)	2 (7)	0 (0)	0.51
Time from intubation to ECCO ₂ R initiation (days)	2 [1–6]	2 [1–4]	4 [1–9]	0.27

Values given as number (%) or median [Interquartile range]

Success group: ≤ 3 ml/kg of predicted body weight, Failure group: > 3 ml/kg of predicted body weight, ECCO₂R: extracorporeal carbon dioxide removal, SOFA: Sepsis-related Organ Failure Assessment, SAPS: simplified acute physiology score, ARDS: acute respiratory distress syndrome, ICU: intensive care unit, SIRS: systemic inflammatory response syndrome

Primary endpoint, success of ultra-low volume ventilation

The proportion of sessions during which a $V_t \leq 3$ ml/kg PBW at 24 h after the start of ECCO₂R was successfully achieved for at least 12 h was 40.0% (confidence interval 25.3–54.6%) (18 out of 45). High blood flow ECCO₂R devices were used in 17 out of 18 sessions (94.4%) in the success group compared to 3 out of 27 sessions (11.1%) in the failure group ($p < 0.001$) (Table 2). After multivariate analysis, only blood flow rate was retained in the final model and was significantly associated with success of ultra-low volume ventilation (adjusted OR per 100 ml/min increase 1.51 (95% CI 1.21–1.90, $p = 0.0003$).

Table 2 Overall respiratory variables at the start of ECCO₂R, before ultraprotective ventilation, and comparison between the failure group and the success group

Sessions characteristics	Overall sessions (n=45)	Failure group (n=27)	Success group (n=18)	p-value
V _T (ml/kg)	5.9 [5.5–6.0]	6.0 [5.7–6.0]	5.7 [4.9–6.0]	0.21
V _T (ml)	390 [350–420]	395 [340–420]	385 [360–410]	0.87
Respiratory rate (breaths/min)	26 [24–30]	26 [22–30]	26 [25–30]	0.94
V _E (L/min)	9.6 [8.1–11.8]	10.0 [8.2–12.1]	9.6 [8.3–11.5]	0.89
PEEP (cmH ₂ O)	10 [8–12]	10 [8–12]	10 [7–11]	0.23
Pplat (cmH ₂ O)	28 [22–31]	27 [21–29]	29 [24–33]	0.08
Driving pressure (cmH ₂ O)	17.0 [12.5–22.0]	14.0 [10.3–18.8]	20.0 [16.3–22.8]	0.018
Cstat,r,s (ml/cmH ₂ O)	25 [17–31]	27 [20–36]	20 [17–26]	0.052
Mechanical power (J/min)	28 [24–36]	30 [24–37]	28 [25–36]	0.42
Ventilatory ratio	1.74 [1.47–2.28]	1.87 [1.48–2.37]	1.64 [1.40–2.21]	0.68
PaCO ₂ (mmHg)	46 [39–56]	47 [39–55]	41 [39.3–59.8]	0.87
pH	7.33 [7.25–7.42]	7.32 [7.25–7.41]	7.33 [7.24–7.42]	0.72
FiO ₂	0.70 [0.50–0.90]	0.65 [0.45–0.8]	0.80 [0.60–1.00]	0.11
PaO ₂ (mmHg)	77 [63–101]	78 [71–98]	72 [63–103]	0.33
PaO ₂ /FIO ₂	128 [90–178]	154 [99–187]	116 [74–161]	0.09
Mode of ventilation				
Mandatory	43 (95)	25 (93)	18 (100)	0.66
Spontaneous	2 (4)	2 (7)	0 (0)	0.66
Adjunctive ARDS treatments before ECCO ₂ R				
Two or more adjunctive treatments	19 (42)	8 (30)	11 (61)	0.036
Muscle paralysis	41 (91)	23 (85)	18 (100)	0.24
Prone position	17 (38)	8 (29)	9 (50)	0.29
Pulmonary vasodilator	7 (16)	1 (4)	6 (33)	0.02

All statistically significant (p-value < 0.05) results appear in bold

Values given as number (%) or median [Interquartile range]

Success group: ≤ 3 ml/kg of predicted body weight, Failure group: > 3 ml/kg of predicted body weight, V_T: tidal volume, V_E: minute ventilation, driving pressure = P_{PLAT} minus PEEP, PEEP: positive end-expiratory pressure, Pplat: end-inspiratory plateau pressure, PaCO₂: partial pressure of arterial CO₂, PaO₂/FIO₂: ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO₂/FIO₂), ARDS: Acute respiratory distress syndrome, ECCO₂R: extracorporeal carbon dioxide removal, Cstat,r,s: static respiratory compliance (ml/cmH₂O) = tidal volume divided by Pplat minus PEEP

Secondary endpoints

Respiratory variables over time

In the overall cohort, V_T decreased during ECCO 2 R from 5.9 [5.5–6.0] ml/kg PBW at the start of ECCO 2 R (H0) to 3.5 [2.3–4.3] ml/kg PBW at 24 h (p < 0.001) (Supplementary Table 1). At 24 h, V_T in the failure group was 4.1 [3.8–4.5] ml/kg PBW compared to 2.1 [1.9–2.5] in the success group (p < 0.001) (Fig. 1A). At 24 h after the start of ECCO 2 R, overall blood flow rates were 500 [400–1500] ml/min, 400 [350–450] ml/min in the failure group versus 1500 [1100–1500] ml/min in the success group (p < 0.001) (Fig. 1B). Decrease in driving pressure was significantly greater in the success group compared to the failure group: absolute reduction of 11.5 [9.0; 13.8] cmH₂O versus 5.0 [2.0; 8.5] cmH₂O (p = 0.007) (Fig. 1C and 1D). There was no difference in variation of Pplat between the two groups (Supplementary Fig. 1) but a significant difference in PEEP (at 24 h increase of 3.5 [0.5; 4.8] cmH₂O in the success group compared to 0 [-2.0; 2.0] cmH₂O in the failure group, p = 0.003) (Fig. 1E, F, Supplemental Table 4). At 24 h, mechanical power in the failure group was 16 [15–22] J/min compared to 7 [6–10] in the success group (p < 0.001). Gas exchanges variations over time during ECCO 2 R are reported in Fig. 2. Overall, PaCO₂ and pH were stable throughout the

procedure (46 [39–56] mmHg and 7.33 [7.25–7.42] respectively at baseline to 46 [40–54] mmHg and 7.34 [7.31–7.44] at 24 h). PaCO₂ and pH were not statistically different between the groups at 24 h while the respiratory rate was significantly lower in the success group than in the failure group (20 [18–25] breaths/min compared to 24 [21–26] breaths/min, p = 0.039). Evolution over time of respiratory variables in each group can be found in the Supplementary Tables 2 and 3. Additional analysis comparing type of intervention (low versus high blood flow) can be found in the Supplementary Fig. 2. Variation of tidal volume was correlated with variation of driving pressure with high blood flow rates but not with low blood flow rates.

Table 3 Overall respiratory variables and ECCO₂R technical characteristics at 24 h after ECCO₂R start and comparison between the failure group and the success group

Sessions characteristics	Overall sessions (n=45)	Failure group (n=27)	Success group (n=18)	p-value
V _T (ml/kg)	3.5 [2.3–4.3]	4.1 [3.8–4.5]	2.1 [1.9–2.5]	<0.001
V _T (ml)	220 [150–280]	280 [235–300]	150 [113–180]	<0.001
Respiratory rate (breaths/min)	24 [21–26]	24 [21–26]	20 [18–25]	0.12
V _E (L/min)	4.8 [3.1–6.5]	6.2 [5.0–7.3]	3.0 [2.8–3.8]	<0.001
PEEP (cmH ₂ O)	10 [8–14]	10 [8–12]	13 [9–15]	0.08
Pplat (cmH ₂ O)	20 [17–24]	20 [16–22]	22 [20–24]	0.08
Driving pressure (cmH ₂ O)	8 [6–12]	8 [7–12]	10 [5–13]	0.78
Cstat _{rs} (ml/cmH ₂ O)	30 [17–37]	34 [26–39]	18 [13–28]	0.02
Mechanical power (J/min)	12 [7–16]	16 [15–22]	7 [6–10]	<0.001
Ventilatory ratio	0.93 [0.46–1.31]	1.31 [1.01–1.54]	0.46 [0.36–0.67]	<0.001
PaCO ₂ (mmHg)	46 [40–54]	50 [43–55]	46 [40–54]	0.25
pH	7.34 [7.31–7.44]	7.34 [7.26–7.46]	7.36 [7.33–7.41]	0.72
FIO ₂	0.60 [0.45–0.80]	0.50 [0.40–0.75]	0.60 [0.50–0.80]	0.33
PaO ₂ (mmHg)	71 [59–90]	82 [60–90]	67 [56–89]	0.44
PaO ₂ /FIO ₂	134 [94–185]	142 [100–178]	119 [82–179]	0.23
ECCO ₂ R cannulas sizes				
Double lumen 13 Fr cannula	11 (24)	11 (41)	0 (0)	<0.001
Double lumen 15 Fr cannula	14 (31)	13 (48)	1 (6)	0.003
Double lumen 18 Fr cannula	1 (2)	1 (4)	0 (0)	0.99
Double lumen 24 Fr cannula	18 (40)	2 (7)	16 (89)	<0.001
Two single lumen cannulas (19 Fr and 17 Fr)	1 (2)	0 (0)	1 (6)	0.99
ECCO ₂ R cannulas insertion site				
Femoral vein	35 (78)	19 (70)	16 (89)	0.12
Internal jugular vein	9 (20)	8 (30)	1 (6)	0.12
Femoral and jugular	1 (2)	0 (0)	1 (6)	0.99
Type of ECCO ₂ R device				
Low blood flow	25 (56)	24 (89)	1 (6)	<0.001
High blood flow	20 (44)	3 (11)	17 (94)	<0.001

All statistically significant (p-value < 0.05) results appear in bold

Values given as number (%) or median [Interquartile range]

Success group: ≤ 3 ml/kg of predicted body weight, Failure group: > 3 ml/kg of predicted body weight, V_T: tidal volume, V_E: minute ventilation, driving pressure = P_{PLAT} minus PEEP, PEEP: positive end-expiratory pressure, Pplat: end-inspiratory plateau pressure, PaCO₂: partial pressure of arterial CO₂, PaO₂/FIO₂: ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO₂/FIO₂), ARDS: Acute respiratory distress syndrome, ECCO₂R: extracorporeal carbon dioxide removal, Cstat_{rs}: static respiratory compliance (ml/cmH₂O) = tidal volume divided by Pplat minus PEEP, Fr: French, Low blood flow ECCO₂R devices: blood flow rates inferior to 500 ml/min, high blood flow ECCO₂R devices: blood flow rates superior to 1000 ml/min

Safety

ECCO₂R-related adverse events are all reported in Table 4. Thrombocytopenia, recorded in 15 out of 45 sessions, was the most frequent adverse event, without significant difference between groups (44.4% in the success group versus 25.9% in the failure group, p = 0.21). No event of circuit or membrane coagulation was recorded in the success group versus 7 events

(25.9%) in the failure group. One patient suffered from an intracerebral hematoma during ECCO₂ R, he had severe coagulopathy unrelated to ECCO₂ R at the time.

Outcomes

Overall 90-day survival rate was 44% (18 out of 41 patients). The 90-day survival rate was 63% (15 out of 24 patients) in the failure group versus 18% (3 out of 17 patients) in the success group ($p = 0.0004$). Overall duration of mechanical ventilation was 18 [9–30] days without significant difference between groups. Two patients were switched to extracorporeal membrane oxygenation (ECMO) because of worsening of PaO₂/FiO₂ ratio




Fig. 1 Evolution over time of tidal volume, blood flow rate, driving pressure and positive end-expiratory pressure. Median, 1st and 3rd quartiles values of tidal volume (VT) (A), blood flow rate (B), driving pressure ($\Delta P = P_{PLAT}$ minus PEEP) (C) and PEEP (E) at the start of ECCO₂R (H0), 4, 24, 48 h after initiation of ECCO₂R in the failure group (> 3 ml/kg of predicted body weight) and in the success group (≤ 3 ml/kg of predicted body weight). Median, 1st and 3rd quartiles values of variation of driving pressure ($\Delta P = P_{PLAT}$ minus PEEP) (D), positive end-expiratory pressure (PEEP) (F) from the start of ECCO₂R (H0) to 4, 24, 48 h after initiation of ECCO₂R in the failure group (> 3 ml/kg of predicted body weight) and in the success group (≤ 3 ml/kg of predicted body weight). * $p < 0.05$ between groups, NS: not significant

Table 4 ECCO₂R-related adverse events

ECCO ₂ R-related adverse events	Overall sessions (n = 45)	Failure group (n = 27)	Success group (n = 18)	p-value
Mechanical				
Catheter-related				
Arterial insertion	1 (2)	0 (0)	1 (6)	0.40
Insertion difficulties	0 (0)	0 (0)	0 (0)	0.99
Accidental catheter removal	0 (0)	0 (0)	0 (0)	0.99
Device-related				
Pump malfunction	2 (4)	2 (7)	0 (0)	0.51
Membrane lung clotting	7 (16)	7 (26)	0 (0)	0.031
Cannula thrombosis	0 (0)	0 (0)	0 (0)	0.99
Air embolism	0 (0)	0 (0)	0 (0)	0.99
Tubing rupture	0 (0)	0 (0)	0 (0)	0.99
Clinical				
Hemolysis	3 (7)	1 (4)	2 (11)	0.55
Significant bleeding	2 (4)	0 (0)	2 (11)	0.15
Pneumothorax	0 (0)	0 (0)	0 (0)	0.99
Hemodynamic instability	7 (16)	4 (15)	3 (17)	0.99
Thromboembolic complications	0 (0)	0 (0)	0 (0)	0.99
Catheter-related bloodstream infections	0 (0)	0 (0)	0 (0)	0.99
Thrombocytopenia	15 (33)	7 (26)	8 (44)	0.20
Neurologic complications	1 (2)	0 (0)	1 (6)	0.40

All statistically significant (p-value < 0.05) results appear in bold

Number of adverse events per session, n (%)

ECCO₂R: extracorporeal carbon dioxide removal. ECCO₂R-related adverse events' definitions are given in the [Supplemental appendix](#)

Discussion

In acute respiratory failure ICU patients, ultra-low volume ventilation (≤ 3 ml/kg PBW) was feasible for at least 12 h in 18 out of 45 sessions (40.0%) of ECCO 2R sessions (confidence interval 25.3–54.6%). Higher blood flow rates were significantly associated with the success of ventilation with tidal volume ≤ 3 ml/kg PBW. Ventilation with $V_t \leq 3$ ml/kg PBW was significantly associated with a greater reduction of driving pressure and lower mechanical power compared to the failure group.

Veno-venous ECCO 2 R devices form a broad heterogeneous group. They are classically divided into low blood flow and high blood flow ECCO 2 R devices [22]. Regarding clinical data, two main indications have fueled clinical studies: acute hypoxemic respiratory failure and acute decompensation of chronic obstructive pulmonary disease (COPD) [23, 24]. Three studies with relatively small number of patients succeeded in implementing ultra-protective ventilation facilitated by low flow veno-venous ECCO 2 R devices. In these studies, V_t was reduced to approximately 4 ml/kg PBW (from 3.9 to 4.29) [12, 25, 26]. Neither hypercapnic acidosis nor major adverse events occurred. The SUPERNOVA pilot study was the first study that included low and high blood flow ECCO 2 R devices. It was a feasibility and safety study that included 95 patients with moderate ARDS [21]. The main endpoint was the proportion of patients who achieved ultra-protective ventilation (4 ml/kg PBW) by 8 h after the start of ECCO 2 R (78%; 95% confidence interval 68–89%). Two randomized controlled studies tried to lower the V_t less or equal than 3 ml/kg PBW. The first one (XTRAVENT study) used an

arterio-venous ECCO 2 R device, which is seldom used nowadays, and patients never reached a tidal volume of 3 ml/kg in the ECCO 2 R group [27]. The second one is a recent large randomized controlled trial which included 412 moderate to severe ARDS patients and used low blood flow ECCO 2 R devices (REST study) [16]. Again, the ECCO 2 R group failed to achieve the 3 ml/kg PBW objective for Vt and there was no difference in the primary outcome (90-day mortality). On day 2 post randomization the reduction in Vt from the baseline was modest, dropping from 6.3 to 4.5 ml/ kg PBW. Moreover, this reduction was paired with an increase in respiratory rate and in PaCO₂ which could be explained by an insufficient CO₂ removal by the ECCO 2 R device used




Fig. 2 Evolution over time of gas exchanges. Median, 1st and 3rd quartiles values of pH (A), partial pressure of arterial CO₂ (PaCO₂) (B), ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO₂/FiO₂) (C) at the start of ECCO₂R (H0), 4, 24, 48 h after initiation of ECCO₂R in the failure group (> 3 ml/kg of predicted body weight) and in the success group (≤ 3 ml/kg of predicted body weight). **p*<0.05 between groups, NS: not significant

Feasibility

We successfully reached a tidal volume less or equal to 3 ml/kg PBW at 24 h of the start of ECCO₂R in 18 out of 45 sessions (40.0%) sessions. The main factor associated with success was blood flow rates (adjusted OR per 100 ml/min increase 1.51 (95%CI 1.21–1.90, *p* = 0.0003). The median tidal volume was 2.1 ml/kg PBW in the success group at 24 h. To our knowledge, no study reports such low tidal volumes with ECCO₂R devices. Previous studies with ECCO₂R did not reach comparable Vt, either because there were not designed to or because they failed to achieve the Vt ≤ 3 ml/kg PBW objective. The main plausible cause for this failure when studying previous reports is insufficient CO₂ removal. Decarboxylation depends on extracorporeal blood flow and gas flow when considering similar gas exchangers and PaCO₂ [28]. The decarboxylation index was recently described (product of

extracorporeal blood flow and gas flow) and found to be linearly associated with extracorporeal CO₂ removal. The authors also report that significant extracorporeal blood flow values must be used in order to obtain an effective decarboxylation index and clinically relevant CO₂ removal [29]. Combes et al. performed a secondary analysis of the SUPERNOVA trial and found that V_t of 4 ml/kg have been obtained more frequently and with a lower rate of adverse events by devices with higher CO₂ extraction (membrane area of 1.30 m² ; blood flow between 800 and 1000 ml/min)[30]. Our results support these findings.

Efficiency

While V_t was reduced, driving pressure was also significantly decreased. Variation of driving pressure at 24 h in the success group (from 20 [16–23] to 9.5 [5–13], $p < 0.001$) cmH₂O was superior to that of the failure group. Comparatively, in the REST trial, driving pressure was decreased from 14.9 to 11.1 cmH₂O in the ECCO 2R group. In an additional analysis (supplementary Fig. 2), we found a correlation between decrease of V_t and decrease of driving pressure only in the high blood flow rate group. Mechanical power, which reflects all the components potentially associated with VILI (airway pressures (P_{plat}, PEEP), volume (V_t), flow and respiratory rate [19]) was significantly lower in the success group at 24 h (Supplementary Fig. 1 and Supplementary Table 4). Finally, despite the significant decrease in V_t and respiratory rate, pH and PaCO₂ stayed within physiological ranges, and no hypercapnic acidosis occurred, respiratory rate was even lower at 24 h in the success group (See Supplementary Tables 1-2-3).

Safety

In the overall population, thrombocytopenia was the most frequent adverse event (33.3% of all sessions). However, compared to previously published studies on ECCO₂R, our cohort included patients with multiple risks of thrombocytopenia such as cirrhosis, sepsis, surgery, acute gastrointestinal bleeding. These patients are usually excluded from ECCO₂R studies (Supplementary Table 5). No significant worsening of hypoxemia related to the implementation of ECCO 2R and low tidal volumes was recorded, as it has been reported in other studies [31]. The success group was not associated with more adverse events than the failure group. Circuit or membrane coagulation happened in 7 sessions (15.6%) in the failure group, 5 events during sessions with anti- coagulation and 2 events during sessions without anticoagulation.

Limits

This study bears some obvious limits inherent to its retrospective methodology. The decision to start ultraprotective ventilation facilitated by ECCO₂R was made as a team including clinicians in charge of the patient. Moreover, when this decision was reached, the choice of the ECCO₂R device and its resulting consequences (cannula size, blood flow rate) were not randomized but left to clinicians' decision. Consequently, the two groups display a difference in driving pressure at baseline as well as PaO₂/FiO₂ (although not significant). One hypothesis is that high flow ECCO₂R devices were spontaneously the preferred approach, by the clinicians in charge, in more severe patients. Because of this difference, we can only speculate on the effect of high blood flow devices on tidal volume in patients with high compliance and low driving pressure. Indeed, in our cohort, patients with high compliance and low driving pressure before ECCO₂R start were mostly treated with low blood flow devices. Low survival rates in our cohort could be explained by the severity of our patients at admission. Indeed, overall SAPS II score was 52 [36–62] and SOFA score was 10 [7–13]. Both these scores reflect high predicted ICU mortality [17, 18]. Patients in our cohort are usually excluded from other ECCO₂R-related studies: patients at high hemorrhagic risk, patients with cirrhosis (Child–Pugh Score \geq B) or liver failure, patients under high doses of norepinephrine [27] (Supplementary Table 5). However, it should be noted that use made by the clinicians of the ECCO₂R devices and of the ventilation strategies could impact outcomes of our patients, which implies caution in the decision to start these devices. Finally, we included all patients treated with ECCO₂R in our ICU which may have limited homogeneity of our population and therefore limit interpretability of the results.

Future directions

Our results point to the importance of high blood flow rates to achieve ultra-low volume ventilation. Future ECCO₂R related studies should differentiate low and high blood flow ECCO₂R devices as they have different efficacy and objectives. This study was not designed to assess superiority of one type of device over the other. However, with our results we could help better design future trials as high blood flow ECCO₂R devices seem to allow a lower V_t and driving pressure. Given the results of our study and previously published data, we could consider using high blood flow ECCO₂R devices in future studies that would assess clinical benefits of ultra-low volume ventilation.

Conclusion

Ultra-low volume ventilation (≤ 3 ml/kg PBW) was feasible, Higher blood flow rate was the main factor associated with the success of ultra-low volume ventilation. In future ECCO2R-related studies, blood flow should be considered in order to achieve effective ultra-low volume ventilation.

Acknowledgements

We thank Dr Julie Carr for proofreading the English of this manuscript.

Author contributions

CM had a major role in the acquisition of data as well as writing the manuscript. TR and AP had a major role in the acquisition of data. TR, YA, MC, CLB, JP, IL made substantial contributions to the writing of the manuscript. ADJ made substantial contributions to the conception of the work as well as contributions to the draft and revisions of the work. ADJ and NM had a major role in analysis of the data. YA, MC, JP, CLB, IL made substantial contributions to the conception of the work and interpretation of data. SJ was a substantial contributor to designing the work as well as interpretation of the data. SJ revised the work in its entirety. All authors read and approved the final manuscript.

Funding

Institutional University Hospital of Montpellier; 34000, France.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The institutional ethics committee reviewed the retrospective use of anonymous data for scientific purpose and waived the need to obtain informed written consent. The Institutional Review Board (IRB) of Montpellier University Hospital approved the study (2019_IRB-MTP_05-25).

Consent for publication

Not applicable.

Competing interests

Pr Jaber reports receiving consulting fees from Drager, Medtronic, Mindray, Fresenius, Baxter, and Fisher & Paykel. Pr De Jong reports receiving remuneration for presentations from Medtronic, Drager and Fisher & Paykel. Dr Monet reports receiving remuneration for presentations from Medtronic. The other authors declare that they have no competing interests.

References

1. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. *JAMA*. 2016;315(8):788–800. - DOI - PubMed
2. Behrendt CE. Acute respiratory failure in the United States: incidence and 31-day survival. *Chest*. 2000;118(4):1100–5. - DOI - PubMed
3. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. *N Engl J Med*. 2013;369(22):2126–36. - DOI - PubMed
4. Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. *Intensive Care Med*. 2006;32(1):24–33. - DOI - PubMed
5. Plötz FB, Slutsky AS, van Vught AJ, Heijnen CJ. Ventilator-induced lung injury and multiple system organ failure: a critical review of facts and hypotheses. *Intensive Care Med*. 2004;30(10):1865–72. - DOI - PubMed
6. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med*. 2000;342(18):1301–8. - DOI
7. Futier E, Constantin JM, Paugam-Burtz C, Pascal J, Eurin M, Neuschwander A, et al. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. *N Engl J Med*. 2013;369(5):428–37. - DOI - PubMed
8. Grasso S, Stripoli T, De Michele M, Bruno F, Moschetta M, Angelelli G, et al. ARDSnet ventilatory protocol and alveolar hyperinflation: role of positive end-expiratory pressure. *Am J Respir Crit Care Med*. 2007;176(8):761–7. - DOI - PubMed
9. Terragni PP, Rosboch G, Tealdi A, Corno E, Menaldo E, Davini O, et al. Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. *Am J Respir Crit Care Med*. 2007;175(2):160–6. - DOI - PubMed
10. Hager DN, Krishnan JA, Hayden DL, Brower RG, ARDS Clinical Trials Network. Tidal volume reduction in patients with acute lung injury when plateau pressures are not high. *Am J Respir Crit Care Med*. 2005;172(10):1241–5. - DOI - PubMed - PMC
11. Needham DM, Colantuoni E, Mendez-Tellez PA, Dinglas VD, Sevransky JE, Dennison Himmelfarb CR, et al. Lung protective mechanical ventilation and two year survival in patients with acute lung injury: prospective cohort study. *BMJ*. 2012;5(344): e2124. - DOI
12. Terragni PP, Del Sorbo L, Mascia L, Urbino R, Martin EL, Birocco A, et al. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. *Anesthesiology*. 2009;111(4):826–35. - DOI - PubMed
13. Terragni P, Ranieri VM, Brazzi L. Novel approaches to minimize ventilator-induced lung injury. *Curr Opin Crit Care*. 2015;21(1):20–5. - DOI - PubMed
14. Fitzgerald M, Millar J, Blackwood B, Davies A, Brett SJ, McAuley DF, et al. Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. *Crit Care Lond Engl*. 2014;18(3):222. - DOI
15. Millar JE, Boyle AJ, Drake TM, Adams CE, Glass AW, Blackwood B, et al. Extracorporeal carbon dioxide removal in acute hypoxaemic respiratory failure: a systematic review, Bayesian meta-analysis and trial sequential analysis. *Eur Respir Rev Off J Eur Respir Soc*. 2022;31(166): 220030. - DOI

16. McNamee JJ, Gillies MA, Barrett NA, Perkins GD, Tunnicliffe W, Young D, et al. Effect of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal vs standard care ventilation on 90-day mortality in patients with acute hypoxemic respiratory failure: the REST randomized clinical trial. *JAMA*. 2021;326(11):1013–23. - DOI - PubMed - PMC
17. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. *JAMA*. 2001;286(14):1754–8. - DOI - PubMed
18. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA*. 1993;270(24):2957–63. - DOI - PubMed
19. Gattinoni L, Tonetti T, Cressoni M, Cadringer P, Herrmann P, Moerer O, et al. Ventilator-related causes of lung injury: the mechanical power. *Intensive Care Med*. 2016;42(10):1567–75. - DOI - PubMed
20. Dianti J, McNamee JJ, Slutsky AS, Fan E, Ferguson ND, McAuley DF, et al. Determinants of effect of extracorporeal CO₂ removal in hypoxemic respiratory failure. *NEJM Evid*. 2023;2(5):EVIDoa2200295. - DOI - PubMed
21. Combes A, Fanelli V, Pham T, Ranieri VM, European Society of Intensive Care Medicine Trials Group and the “Strategy of Ultra-Protective lung ventilation with Extracorporeal CO₂ Removal for New-Onset moderate to severe ARDS” (SUPERNOVA) investigators. Feasibility and safety of extracorporeal CO₂ removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. *Intensive Care Med*. 2019;45:592–600. - DOI - PubMed
22. Combes A, Brodie D, Aissaoui N, Bein T, Capellier G, Dalton HJ, et al. Extracorporeal carbon dioxide removal for acute respiratory failure: a review of potential indications, clinical practice and open research questions. *Intensive Care Med*. 2022;48(10):1308–21. - DOI - PubMed
23. Morelli A, Del Sorbo L, Pesenti A, Ranieri VM, Fan E. Extracorporeal carbon dioxide removal (ECCO₂R) in patients with acute respiratory failure. *Intensive Care Med*. 2017;43:519–30. - DOI - PubMed
24. Sklar MC, Beloncle F, Katsios CM, Brochard L, Friedrich JO. Extracorporeal carbon dioxide removal in patients with chronic obstructive pulmonary disease: a systematic review. *Intensive Care Med*. 2015;41(10):1752–62. - DOI - PubMed
25. Fanelli V, Ranieri MV, Mancebo J, Moerer O, Quintel M, Morley S, et al. Feasibility and safety of low-flow extracorporeal carbon dioxide removal to facilitate ultra-protective ventilation in patients with moderate acute respiratory distress syndrome. *Crit Care Lond Engl*. 2016;10(20):36. - DOI
26. Schmidt M, Jaber S, Zogheib E, Godet T, Capellier G, Combes A. Feasibility and safety of low-flow extracorporeal CO₂ removal managed with a renal replacement platform to enhance lung-protective ventilation of patients with mild-to-moderate ARDS. *Crit Care Lond Engl*. 2018;22(1):122. - DOI
27. Bein T, Weber-Carstens S, Goldmann A, Müller T, Staudinger T, Brederlau J, et al. Lower tidal volume strategy (≈ 3 ml/kg) combined with extracorporeal CO₂ removal versus ‘conventional’ protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. *Intensive Care Med*. 2013;39(5):847–56. - DOI - PubMed - PMC

28. Karagiannidis C, Kampe KA, Sipmann FS, Larsson A, Hedenstierna G, Windisch W, et al. Veno-venous extracorporeal CO₂ removal for the treatment of severe respiratory acidosis: pathophysiological and technical considerations. *Crit Care Lond Engl.* 2014;18(3):R124. - DOI
29. Laumon T, Courvalin E, Dagod G, Deras P, Girard M, Martinez O, et al. Performance of the decarboxylation index to predict CO₂ removal and minute ventilation reduction under extracorporeal respiratory support. *Artif Organs.* 2023;47(5):854–63. - DOI - PubMed
30. Combes A, Tonetti T, Fanelli V, Pham T, Pesenti A, Mancebo J, et al. Efficacy and safety of lower versus higher CO₂ extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study. *Thorax.* 2019;74(12):1179–81. - DOI - PubMed
31. Gattinoni L. Ultra-protective ventilation and hypoxemia. *Crit Care Lond Engl.* 2016;20(1):130. - DOI

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The institutional ethics committee reviewed the retrospective use of anonymous data for scientific purpose and waived the need to obtain informed written consent. The Institutional Review Board (IRB) of Montpellier University Hospital approved the study (2019_IRB-MTP_05-25). Consent for publication: Not applicable. Competing interests: Pr Jaber reports receiving consulting fees from Drager, Medtronic, Mindray, Fresenius, Baxter, and Fisher & Paykel. Pr De Jong reports receiving remuneration for presentations from Medtronic, Drager and Fisher & Paykel. Dr Monet reports receiving remuneration for presentations from Medtronic. The other authors declare that they have no competing interests.